Local News

• Broad Institute gets $400 million gift from founders  The Broad Institute of Harvard and MIT, a world-renowned genetics research operation founded just five years ago, has received an additional $400 million endowment from founding donors Eli and Edythe Broad.
  Boston Business Journal September 04, 2008  Mark Hollmer
• NxStage announces blood tubing set agreement with DaVita  NxStage Medical announced that it has signed a one-year extension of its existing agreement with DaVita to supply blood tubing sets to DaVita centers.
  NxStage Medical, Inc. September 04, 2008  
• Abbott recognized on Dow Jones Sustainability Index (DJSI) for fourth consecutive year  Abbott announced that it was recognized on the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the fourth consecutive year.
  Abbott September 04, 2008  
• Amgen and Wyeth statement on the FDA Safety Announcement regarding TNF blockers  Amgen and Wyeth Pharmaceuticals issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R), Enbrel(R), Humira(R) and Cimzia(R)).
  Amgen September 04, 2008  
• Percutaneous coronary intervention with CYPHER(R) stent comparable to bypass surgery  Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent was comparable to bypass surgery in key safety endpoints in patients with multi-vessel disease and diabetes.
  Johnson & Johnson September 04, 2008  
• Isis receives notices of allowance that expands scope of key RNA therapeutic patents  Isis Pharmaceuticals, Alnylam Pharmaceuticals, and the companies' joint venture Regulus Therapeutics announced that the United States Patent and Trademark Office has granted notices of allowance for two U.S. patent applications that further enhance the scope of Isis' "Crooke" patent estate.
  Isis Pharmaceuticals, Inc. September 04, 2008  
• Monsanto's Roundup Ready 2 Yield(TM) Soybeans receive China regulatory approval  Monsanto Company announced it has received regulatory approval in China for the importation of Roundup Ready 2 Yield(TM) soybeans. China imports accounted for approximately 38 percent of U.S. soybean exports in 2007, making it the largest purchaser of U.S. soybeans.
  Monsanto Company September 04, 2008  
• Amrubicin receives FDA Fast Track Designation for the treatment of small cell lung cancer  Celgene announced that Amrubicin has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer after first-line chemotherapy.
  Celgene Corporation September 04, 2008  
• FDA assigns priority review to GTC Biotherapeutics' ATryn(R)  The US Food and Drug Administration, or FDA, has assigned Priority Review to GTC Biotherapeutics' Biologic License Application, or BLA, for ATryn(R). Under Priority Review, the FDA's target date for action on the BLA is February 7, 2009.
  GTC Biotherapeutics, Inc. September 04, 2008  
• USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040  Forest Laboratories announced that an Office Action in the Reexamination of U.S. Patent No. 6,545,040 ("the '040 patent") was received from the U.S. Patent and Trademark Office ("USPTO") by Janssen Pharmaceutica N.V., the patent holder of the '040 patent.
  Forest Laboratories, Inc. September 04, 2008  

   (next 10 articles)